** Shares of pharmaceuticals co JUBA.NS fall as much as
10.2% at 473.05 rupees, lowest since June 5, 2020
** JUBA marks its their biggest intraday pct loss since Feb.
24. 2021
** Co on Friday reported https://bit.ly/3HNDwfz consolidated
net profit for Dec-quarter of 509.9 mln rupees ($6.83 mln), a
nearly 84% slump y-o-y; sales dropped to 12.98 bln rupees from
17.44 bln rupees year ago
** Co said its pharma business saw lower profits due to
voluntary withdrawal of blood pressure drug Losartan, continued
tapering of COVID-19 related one-off deals and pricing pressure
in the U.S. generics market
** Near-to-medium-term growth to remain under pressure due
to continued delay in radiopharma recovery and pricing pressures
in the US. - says ICICI Securities; downgrades rating to 'hold'
from 'buy'
** More than 489,000 shares traded by 0654 GMT, 5.6x times
their 30-day avg
** Four of 6 brokerages rate the stock "buy" or higher, 1
"hold" and 1 "sell"; their median PT is 750 rupees - Refinitiv
data
** Up to last close, JUBA had fallen 10.2% this year; down
nearly 20% in 2021
($1 = 74.7080 Indian rupees)
(Reporting by Rama Venkat in Bengaluru)
((ramavenkat.raman@thomsonreuters.com; https://twitter.com/ramavenkat0607;))